Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is ISRG Winning the Next Phase of Robotic Surgery Beyond Urology?
ISRG is expanding robotic surgery beyond urology as general surgery and newer specialties gain traction, creating fresh avenues for long-term procedure growth.
ISRG Q2 Earnings Call Signals Durable Demand & U.S. Caution
ISRG pairs durable platform demand and higher margin guidance with caution on softer U.S. procedure growth and deferred care.
Intuitive Surgical Fell 37% to $355 With This Wall Street Pro Is Calling for $685
Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) trades at $356.83, while the average Wall Street price target sits at $484.40.
ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?
ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.
Why Intuitive Surgical, Inc. (ISRG) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is ISRG Stock Worth Buying as Growth Stays Strong but Risks Rise
ISRG's strong procedure growth, recurring revenue and cash position support its case, but tariffs, mix shifts and placement risks cloud the outlook.
ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure
ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.
ISRG Growth Story Hinges on Da Vinci 5, Ion and Recurring Revenue
Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.
Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?
Intuitive Surgical's valuation has eased as U.S. procedure growth slows, but margin gains, AI software expansion and global growth could support its premium.
3 Reasons Growth Investors Will Love Intuitive Surgical (ISRG)
Intuitive Surgical (ISRG) possesses solid growth attributes, which could help it handily outperform the market.
